Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 1 to 25 from a total of 87
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
Altuvoct |
Swedish Orphan Biovitrum AB, Schweden |
EU/1/24/1824 | 17.06.2024 | |
Prothromplex NF 500 |
Takeda GmbH |
PEI.H.11717.02.1 | 21.04.2023 | |
Cevenfacta |
Laboratoire francais du Fractionement et des Biotechnologies, Frankreich |
EU/1/22/1664 | 15.07.2022 | |
Octanate 1000 |
CC-Pharma GmbH |
PEI.H.12112.01.1 | 05.07.2021 | |
Beriate 1000 |
CC-Pharma GmbH |
PEI.H.12077.02.1 | 06.05.2021 | |
Beriate 2000 |
Orifarm GmbH |
PEI.H.12092.02.1 | 19.04.2021 | |
IMMUNINE 1200 I.E. |
Orifarm GmbH |
PEI.H.12094.01.1 | 24.03.2021 | |
Octanate 1000 |
Orifarm GmbH |
PEI.H.12088.01.1 | 24.03.2021 | |
Haemate P 1000 I.E. FVIII / 2400 I.E. VWF |
Orifarm GmbH |
PEI.H.12082.01.1 | 24.03.2021 | |
Beriate 2000 |
CC-Pharma GmbH |
PEI.H.12077.01.1 | 10.03.2021 | |
Esperoct |
Novo Nordisk A/S, Dänemark |
EU/1/19/1374 | 20.06.2019 | |
Jivi |
Bayer AG |
EU/1/18/1324 | 22.11.2018 | |
|
Veyvondi |
Baxalta Innovations GmbH |
EU/1/18/1298 | 31.08.2018 | |
|
Adynovi |
Baxalta Innovations GmbH, A |
EU/1/17/1247 | 08.01.2018 | |
|
Fibryga |
Octapharma GmbH |
PEI.H.11879.01.1 | 23.06.2017 | |
|
Refixia |
Novo Nordisk A/S, Denmark |
EU/1/17/1193 | 02.06.2017 | |
|
Vihuma |
Octapharma AB, Stockholm |
EU/1/16/1168 | 13.02.2017 | |
|
Afstyla |
CSL Behring GmbH |
EU/1/16/1158 | 04.01.2017 | |
|
Alprolix |
Swedish Orphan Biovitrum AB (publ) |
EU/1/16/1098 | 12.05.2016 | |
|
Idelvion |
CSL Behring GmbH |
EU/1/16/1095 | 11.05.2016 | |
|
Coagadex |
Bio Products Laboratory Ltd., UK-Hertfordshire |
EU/1/16/1087 | 16.03.2016 | |
|
Kovaltry |
Bayer AG |
EU/1/15/1076 | 18.02.2016 | |
|
FibCLOT |
Laboratoire Français du Fractionnement et des Biotechnologies, F Les Ulis |
PEI.H.11771.01.1 | 05.02.2016 | |
|
Elocta |
Swedish Orphan Biovitrum AB (publ) |
EU/1/15/1046 | 19.11.2015 | |
|
Obizur |
Baxalta Innovations GmbH, A |
EU/1/15/1035 | 11.11.2015 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
